Company also presents data supporting potential of Adenosine Gene Signature to serve as a biomarker to identify patients that are likely to respond to CPI-006 and ciforadenant Company to host investor ...

Corvus Pharmaceuticals (CRVS) is in the process of evaluating the use of its interleukin-2-inducible T cell kinase [ITK] inhibitor for the treatment of patients with a wide variety of lymphoma types, ...

The cyber insurance industry is likely to go mainstream and is a simple cost of doing business. Here are a few options to consider. Read now Corvus Insurance, a company focused on applying artificial ...

Today, we take our first new look at a small biopharma firm called Corvus Pharmaceuticals in over 18 months. The company is getting closer to moving its primary drug candidate into a potentially ...

BOSTON--(BUSINESS WIRE)--Corvus Insurance, the leading provider of smart commercial insurance products powered by AI-driven risk data, today announced it has secured $100 million in Series C funding ...